EichorEICHOR
Condition: Kras Mutant Solid Tumors Synced from ClinicalTrials.gov · August 08, 2026

Recruiting studies: Kras Mutant Solid Tumors

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

TLN-372 in Advanced KRAS Mutant Solid Tumors
Phase 1 · 11 location(s) · Treeline Biosciences, Inc. · NCT07204340Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C M
Phase 1/Phase 2 · 55 location(s) · Revolution Medicines, Inc. · NCT06128551A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)
Phase 2 · 70 location(s) · Merck Sharp & Dohme LLC · NCT07209111JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
Phase 1/Phase 2 · 4 location(s) · Jacobio Pharmaceuticals Co., Ltd. · NCT06973564Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Phase 1 · 17 location(s) · Revolution Medicines, Inc. · NCT06040541A Phase I/II Study of ABSK141 in Patients With Advanced Solid Tumors ( ABSK141-101 )
Phase 1/Phase 2 · 1 location(s) · Abbisko Therapeutics Co, Ltd · NCT07417189MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
Phase 1 · 52 location(s) · Eli Lilly and Company · NCT06586515Phase I Study of HRS-6093 in Participants With Advanced Solid Tumors Harboring KRAS G12D Mutations
Phase 1 · 2 location(s) · Jiangsu HengRui Medicine Co., Ltd. · NCT07134998Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherap
Phase 1/Phase 2 · 4 location(s) · Auricula Biosciences Inc. · NCT07148128Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
Phase 1 · 9 location(s) · Revolution Medicines, Inc. · NCT07349537Neoadjuvant Treatment of Fulzerasib Plus Cetuximab N01 in KRAS G12C Mutated Locally Advanced Colorectal Cancer With or W
Phase 2 · 1 location(s) · Zhejiang University · NCT07581912TCR-T Cell Therapy on Advanced Solid Tumors
EARLY_Phase 1 · 1 location(s) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · NCT05438667A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
Phase 1 · 12 location(s) · Alterome Therapeutics, Inc. · NCT06835569A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
Phase 1/Phase 2 · 1 location(s) · Blueprint Medicines Corporation · NCT07629960Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Phase 1 · 40 location(s) · TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) · NCT06625775Study of ABO2102 in KRAS-Mutated Solid Tumors
Phase 1 · 1 location(s) · Suzhou Abogen Biosciences Co., Ltd. · NCT07455617A Study of GFH375 in Patients With Advanced Solid Tumors With KRAS G12D Mutations
Phase 1/Phase 2 · 20 location(s) · Genfleet Therapeutics (Shanghai) Inc. · NCT06500676BBO-11818 in Adult Subjects With KRAS Mutant Cancer
Phase 1 · 17 location(s) · TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) · NCT06917079A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)
Phase 1 · 75 location(s) · Merck Sharp & Dohme LLC · NCT05067283A Phase I/IIa Study of JAB-23E73 in Patients With Advanced Solid Tumors Harboring KRAS Gene Alteration
Phase 1/Phase 2 · 32 location(s) · Jacobio Pharmaceuticals Co., Ltd. · NCT06959615A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral On
Phase 1 · 9 location(s) · Kestrel Therapeutics, Inc. · NCT07458347
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →
Eichor
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.